Platform
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by integrating computational science, machine learning with human disease biology to redefine diseases, and generate libraries of compounds that are screened in traditional drug discovery and development assays.
Pipeline
Our lead clinical program, SGM-1019, targets inflammatory pathways identified in both NASH and IBD, offering the potential for a novel, safe and well-tolerated oral therapy for the treatment of these diseases.
News
September 26, 2018
Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer
